evt_8b3fdc85-0aa9-556a-aaac-d5c8ac2c12deAstraZeneca’s COPD antibody gets Phase 3 wins in broader-than-expected population
AstraZeneca’s COPD antibody gets Phase 3 wins in broader-than-expected population
phase3_result
evd_22504791-0aab-5350-85bb-fab40c14a6d3, evd_46af04d9-5425-503d-8f17-3d9767f0fb33, evd_bece9376-054a-58b5-8607-51bdf740efaf, evd_ce9ea4e3-bddd-518c-9e49-10455e6d910b, evd_cec2cf4a-4b0f-5f75-b8a2-dfed8865fa30, evd_d746daa9-7be1-5ea2-9df5-7bdd8a55b381, evd_ef184880-5291-570c-a572-ad1b5fe1cb25fact_be9c77ca-6fbd-5615-b3f1-b2edff0922a5, fact_ff36cab2-7c11-5cbc-ac12-4c7fa57e4801rel_0b9b9771-25ed-5bd6-8c86-e5fa717c97fe, rel_48ea4cc3-43a7-5a8f-8037-704e8fbbc808, rel_61f3365d-d977-5a09-8507-92441bda18f5, rel_e4313468-10d0-507f-8422-f51deec35bc3